Morgan Stanley Vectiv Bio Holding Ag Transaction History

Morgan Stanley

  • $1.23 Trillion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$8.29 - $16.97 $18,494 - $37,860
-2,231 Reduced 98.63%
31 $0
Q3 2022

Nov 14, 2022
BUY
$4.7 - $6.07 $10,485 - $13,542
2,231 Added 7196.77%
2,262 $13,000
Q3 2021

Nov 15, 2021
BUY
$6.7 - $11.54 $207 - $357
31 New
31 $0

Others Institutions Holding VECT

# of Institutions
1
Shares Held
510K
Call Options Held
0
Put Options Held
0
View Full List

About VectivBio Holding AG

VECT Quotes by TradingView
  • Ticker VECT
  • Exchange NASDAQ
  • Description
  • VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...
More about VECT
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email